SCHEMBL25620354

SCHEMBL25620354

COC(=O)Oc1nc2[nH]ccc2cc1C(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK8 P49336 6/20 0.37
▸ CFTR P13569 1/20 0.35
▸ FEN1 P39748 1/20 0.34
▸ PIK3C3 Q8NEB9 1/20 0.34
▸ KDR P35968 2/20 0.33
▸ CDK7 P50613 2/20 0.33
▸ PLK4 O00444 1/20 0.33
▸ DCLK1 O15075 1/20 0.33
▸ ROCK2 O75116 1/20 0.33
▸ PRKD3 O94806 1/20 0.33
▸ MAP4K4 O95819 1/20 0.33
▸ PAK4 O96013 1/20 0.33
▸ CHEK2 O96017 1/20 0.33
▸ INSR P06213 1/20 0.33
▸ CDK1 P06493 1/20 0.33
▸ FES P07332 1/20 0.33
▸ ROS1 P08922 1/20 0.33
▸ PDGFRB P09619 1/20 0.33
▸ PDGFRA P16234 1/20 0.33
▸ FER P16591 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25613169 0.82 BRD4 (0.40) CDK8FEN1KDRMKNK2MAPK14
SCHEMBL25620352 0.82 ATM (0.41) CDK8CFTRFEN1ABL1ALDH1A1
SCHEMBL25613036 0.78 FEN1 (0.36) CDK8FEN1KDRCDK1CDK2
SCHEMBL25613170 0.77 CDK8 (0.44) CDK8CFTRFEN1KDRCDK7
SCHEMBL25613032 0.77 FEN1 (0.38) CFTRFEN1KDRBRD4FGFR1
SCHEMBL25613047 0.76 KDR (0.39) CDK8FEN1KDRCDK1BRD4
SCHEMBL25613433 0.75 FEN1 (0.36) CDK8FEN1KDRBRD4FGFR1
SCHEMBL25613037 0.75 FEN1 (0.39) CDK8CFTRFEN1KDRCDK1
SCHEMBL25613045 0.75 ULK1 (0.39) CDK8CFTRFEN1KDRBRD4
SCHEMBL25613050 0.75 FEN1 (0.39) CDK8FEN1KDRCDK7PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 CDK8 533/4885CFTR 620/4885FEN1 1864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback